Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion
Johnson & Johnson (J&J) announced on November 17 that it entered into an agreement to acquire Halda Therapeutics. The purchase price is $3.05 billion. Founded by Yale scientist, Professor Craig Crews, Halda Therapeutics is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its business lines include... Read More »
JSR Life Sciences to Transfer Crown Bioscience to Adicon Holdings Limited
JSR Life Sciences LLC, a global leader in life sciences materials and services, announced it has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited. The deal will enable Crown Bioscience to operate as a standalone entity under Adicon’s ownership. The transaction, subject to customary closing conditions, is expected to close in 2026. Financial terms were not disclosed. Crown Bioscience is a contract research organization (CRO) specializing in oncology and immuno-oncology drug discovery and development. The company has a comprehensive portfolio of translational oncology services, including its patient-derived xenograft models, tumor... Read More »
GSK Acquires Syndivia’s Preclinical Antibody Drug Conjugate for More than $357 Million
GSK Plc announced on October 29 that it acquired Syndivia’s preclinical antibody-drug conjugate (ADC). Syndivia’s preclinical ADC is in development for the treatment of prostate cancer. Syndivia developed the prostate cancer drug hopeful using its GeminiMab conjugation technology, which the biotech claims can create a unique drug-to-antibody ratio hinge region site-specific ADC. Syndivia is a French biotechnology company focused on the design and development of ADCs. Its proprietary technology enables the creation of next-generation ADCs with optimized therapeutic profiles, aiming to expand treatment options for patients with cancer. GSK, formerly... Read More »
TransCode Therapeutics Acquires Polynoma
TransCode Therapeutics, Inc. announced on October 8 that it entered into an agreement to acquire Polynoma LLC. Polynoma is a privately held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which... Read More »
Pfizer Buys Metsera and its Next-Generation Obesity Portfolio
Pfizer Inc. and Metsera, Inc. jointly today announced on September 22 that the companies have entered into a definitive agreement under which Pfizer will acquire Metsera. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash at closing, for an initial enterprise value of $4.9 billion with a contingent value right of up to $22.50 per share in additional payments. The Boards of Directors of both Metsera and Pfizer have unanimously approved the transaction, which is expected to close in the fourth quarter of 2025. Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
